Home / Market News / $REGN
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

RBC Capital Markets Adjusts Regeneron Pharmaceuticals Price Target to $913

Nov 2, 2026, 2:33 PM UTC · Primary ticker $REGN

RBC Capital Markets has increased its price target for Regeneron Pharmaceuticals (REGN) from $810 to $913, while reiterating a 'Sector Perform' rating. This revision reflects an updated valuation by the analyst firm, which could provide some positive sentiment for the stock, though the maintained rating suggests no fundamental shift in RBC's overall outlook.

RBC Capital Markets has adjusted its price target for Regeneron Pharmaceuticals (REGN) upwards to $913 from $810. This change indicates a more optimistic valuation by RBC analysts regarding REGN's future prospects, likely driven by recent company developments or market trends. While the price target increase is positive, the maintained 'Sector Perform' rating suggests RBC does not see REGN as a significant outperformer compared to its peers. This news primarily affects current and potential investors in Regeneron, offering a revised analyst perspective. In the short term, it could provide a modest boost to investor confidence; long-term implications depend on whether other analysts follow suit or if fundamental company performance justifies the new target. A key opportunity for traders is to assess if this price target revision signals broader positive sentiment that could lead to further upside, or if the 'Sector Perform' rating limits significant sustained gains.

$REGN positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.